Sakakibara H, Hirose K, Matsushita K, Nakamura S, Sato M, Kako K, Suetsugu S
Department of Internal Medicine, School of Medicine, Fujita Health University.
Nihon Kyobu Shikkan Gakkai Zasshi. 1995 Apr;33(4):395-402.
The effects of dietary supplementation with highly purified eicosapentaenoic acid ethyl ester (EPA-E) (MND-21) on asthma symptoms, fatty acids in serum, and generation of leukotriene (LT) C4, LTC5, LTB4 and LTB5 by leukocytes stimulated with calcium ionophore A23187 were studied in 10 patients with bronchial asthma. The patients received nine capsules of MND-21 (2.7 g EPA-E) each day for 12 weeks. Leukocytes obtained from 39 patients with asthma who did not receive EPA-E were used as the control. Fatty acid composition was evaluated by gas chromatography and LT generation was measured by reverse-phase high performance liquid chromatography. EPA-E increased EPA content more than threefold, without changing the quantities of arachidonic acid in serum lipids. Leukocytes obtained from patients given EPA-E for 4 weeks generated less LTC4 (53.5 +/- 23.3 ng/10(7) cells) and LTB4 (24.9 +/- 12.4 ng/10(7) cells) than did those from control patients (142.4 +/- 91.6 ng/10(7) cells and 58.3 +/- 34.8 ng/10(7) cells, respectively). Although significant levels of LTC5 and LTB5 were present after 4 weeks of EPA-E (6.5 +/- 1.9 ng/10(7) cells and 4.6 +/- 2.7 ng/10(7) cells, respectively), generation of total LTC (LTC4 + LTC5) and total LTB (LTB4 + LTB5) were substantially suppressed. Symptoms had improved after two months of EPA-E, but the effect was temporary. We conclude that in patients with asthma, treatment with EPA-E may attenuate leukocyte function without distinctly changing the severity of asthma.
在10例支气管哮喘患者中研究了膳食补充高纯度二十碳五烯酸乙酯(EPA-E,MND-21)对哮喘症状、血清脂肪酸以及钙离子载体A23187刺激的白细胞中白三烯(LT)C4、LTC5、LTB4和LTB5生成的影响。患者每天服用9粒MND-21胶囊(含2.7 g EPA-E),持续12周。将39例未接受EPA-E的哮喘患者获取的白细胞用作对照。通过气相色谱法评估脂肪酸组成,通过反相高效液相色谱法测量LT生成。EPA-E使EPA含量增加了三倍多,而血清脂质中花生四烯酸的量未发生变化。接受EPA-E治疗4周的患者所获取的白细胞生成的LTC4(53.5±23.3 ng/10⁷细胞)和LTB4(24.9±12.4 ng/10⁷细胞)比对照患者的白细胞(分别为142.4±91.6 ng/10⁷细胞和58.3±34.8 ng/10⁷细胞)少。尽管EPA-E治疗4周后LTC5和LTB5有显著水平(分别为6.5±1.9 ng/10⁷细胞和4.6±2.7 ng/10⁷细胞),但总LTC(LTC4 + LTC5)和总LTB(LTB4 + LTB5)的生成受到了显著抑制。EPA-E治疗两个月后症状有所改善,但效果是暂时的。我们得出结论,对于哮喘患者,EPA-E治疗可能会减弱白细胞功能,而不会明显改变哮喘的严重程度。